Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...
Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...
2 天
GlobalData on MSNJ&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ resultsThe company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...
A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...
Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t demonstrate sufficient efficacy in preventing invasive E. coli disease No safety signals ...
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient ...
Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...
Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E. coli disease No safety signals related to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果